Skip to main content

Table 9 Robustness results for dolutegravir

From: A new validated stability-indicating RP-HPLC method for simultaneous quantification of dolutegravir and lamivudine in bulk and pharmaceutical dosage form

S. No.

Parameter

As such method

Used

%RSD for peak area (n = 6)

Average retention time

Plate count

Tailing factor

Resolution

1

Flow rate (± 0.1 mL/min)

1.0 mL/min

0.9 mL/min

0.8

6.687

50185

1.12

23.47

1.0 mL/min

0.9

6.367

55945

1.14

22.51

1.1 mL/min

1.2

6.354

53434

1.06

21.34

2

Column temperature (± 5 °C)

30 °C

25 °C

0.5

6.321

52290

1.11

22.49

30 °C

0.9

6.367

55945

1.16

22.51

35 °C

1.5

6.353

53457

1.07

22.37

3

Mobile phase composition

Buffer:ACN:Methanol, 55:20:30% v/v

55:25:25

0.7

6.322

52235

1.08

22.48

55:20:30

0.9

6.367

55985

1.13

22.51

55:15:35

1.2

6.364

51769

1.04

22.58